OAB and Incontinence

“I view OAB as a problem for many women that hasn't gotten the attention that it's needed over the decades,” says Alexandra Rogers, MD.

At standard stimulation parameters, the Axonics F15 system is expected to function for 15+ years; at lower energy settings, this extends to 20+ years.

Abstracts highlight topics such as sacral neuromodulation and percutaneous tibial nerve stimulation.

The device is indicated for overactive bladder, chronic fecal incontinence, and non-obstructive urinary retention.

The approval was based on results from a pivotal, open-label, single-arm trial that were published in the Journal of Urology.

“The prevalence of incontinence is high and increasing. We recommend routine screening for all women for this condition as a part of preventive health care,” says Ushma J. Patel, MD.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Melissa R. Kaufman, MD, PhD, FACS, discusses the significance of onabotulinumtoxinA treatment in patients with overactive bladder.

"There have been few therapies that have so galvanized management of a urologic condition as what we've witnessed over the past decade regarding the use of onabotulinumtoxinA (Botox) for bladder dysfunction," says Melissa R. Kaufman, MD, PhD, FACS.

In this interview, Alexandra Rogers, MD, discusses how urologists can help patients with OAB feel normal.

“The most notable finding is that more than half of all adult US women experience urinary incontinence,” says Heidi Wendell Brown, MD, MAS, FACOG.

“Patients are overwhelmed by these choices often, and don't really understand the risks and benefits when they're first told about them,” said co-author Anjali Kapur, MD.

“Previous OAB studies could be inadvertently excluding large populations of patients due to language barriers, access to academic centers, collecting research data, or differences in beliefs in health care in general,” said co-author Beth Edelblute, MD, MPH.

“I think there's a disconnect between the patients saying they're interested in these therapies, and the patients that actually go on to [receive] them,” says Jason Kim, MD.

To analyze real-world data of urinary incontinence, Heidi Wendell Brown, MD, MAS, FACOG, Ushma J. Patel, MD, and co-authors conducted a study involving the 2015-2018 National Health and Nutrition Examination Survey (NHANES).

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Howard Goldman, MD, discusses the development of the midurethral sling as a treatment for stress urinary incontinence.

"Introducing something that with a prefashioned sling, [something] we're able to utilize with the patient in an ideal situation just under some deep sedation and local, really opened this up the ability for many more women to be treated and allowed many more physicians to be trained and to utilize this technology," says Howard B. Goldman, MD, FACS.

“Our goal was to educate these patients thoroughly on the risks and benefits of each of these therapies, and try to understand what guides their choice of third line therapy based on their lifestyle and what suits them,” says Anjali Kapur, MD.

"The devices, telemedicine and remote care, and outpatient surgery risk us losing the human connection we had with the patient, as time spent with them is at a premium today," writes Gopal H. Badlani, MD.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Melissa R. Kaufman, MD, PhD, FACS, discusses the innovative use of stem cell–derived treatments in urologic conditions such as stress urinary incontinence.

"The newest frontier of therapy for stress incontinence is regenerative medicine and stem cell–based therapies," says Melissa R. Kaufman, MD, PhD, FACS.

"This analysis of this publication confirms the link between efficacy and the patient perception, and that the results are actually meaningful to the patients as well," says Cornelia Haag-Molkenteller, MD, PhD.

This study underscores how common urinary incontinence is in women, with nearly 1 in 5 Japanese women reporting urinary incontinence related to OAB or SUI in the last month,” said Stephanie Faubion, MD, MBA, medical director of the North American Menopause Society.

“Using a national cohort of older adults with dementia, we…found that donepezil was associated with a 13% increased risk of OAB compared to rivastigmine,” says study author Rajender R. Aparasu, PhD

“We need to understand what the treatment [means] to them as individuals, and how they perceive the benefit of the treatment,” says Cornelia Haag, Molkenteller, MD, PhD.

“This analysis of this publication confirms the link between efficacy and the patient perception, and that the results are actually meaningful to the patients as well,” says Cornelia Haag-Molkenteller, MD. PhD.

The leva Pelvic Health System showed early promise as a noninvasive therapy to alleviate symptoms of fecal incontinence in women.

“Falls are the leading cause of accidental death in seniors, and many people don’t know that having bladder control problems makes you about twice as likely to fall over,” said William Gibson, MBChB, MRCP, PhD.

The approval was based on data from the ROBUST I and ROBUST 3 clinical trials.

“New things are being developed and, I believe, at the moment showing great initiative and resolve,” says Justin Chee, MD.